Skip to main content
HCPCS Q5114 · Level II · Part B drug

Q5114: trastuzumab-dkst (Ogivri), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5114

Billing unit
10 MG
Inj ogivri 10 mg
ASP payment limit
$29.507
October 2026; -7.6% vs July 2026
Practitioner MUE
120
MAI 3
OPPS status
SI K
APC 9341
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q5114 is the Level II code for Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $29.507 per billing unit, down 7.6% from July 2026. The practitioner MUE allows up to 120 units per date of service (MAI 3), so a full 120-unit day is $3,540.84 at the current limit. Under OPPS it carries status indicator K in APC 9341. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. Other HCPCS codes whose descriptor names trastuzumab: Q5113 (biosimilar trastuzumab-pkrb (Herzuma) from Cephalon, LLC); Q5112 (biosimilar trastuzumab-dttb (Ontruzant) from Organon LLC); Q5116 (biosimilar trastuzumab-qyyp (Trazimera) from Pfizer Inc); Q5117 (biosimilar trastuzumab-anns (Kanjinti) from Amgen Inc); Q5146 (biosimilar trastuzumab-strf (Hercessi) from Accord BioPharma, Inc); J9355 (non-biosimilar trastuzumab (Herceptin) from Genentech, Inc). The ASP crosswalk maps 4 NDCs to it, sold as Ogivri by Viatris - Greenstone LLC, Biocon Biologics Inc. No current Billing and Coding Article lists Q5114, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5114 at $29.507 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $31.945 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q5114
QuarterPayment limitPerCoinsurance
October 2026$29.50710 MG20%
July 2026$31.94510 MG—
CMS note: 8% of reference add-on applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 4 NDCs from 2 labelers to Q5114. Report the NDC in the claim's drug segment and bill the number of Q5114 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to Q5114
NDCDrug nameLabelerPackage sizeBilling units / package
67457-0847-44OgivriViatris - Greenstone LLC1 × 142
67457-0991-15OgivriViatris - Greenstone LLC1 × 115
83257-0001-11OgivriBiocon Biologics Inc1 × 115
83257-0004-12OgivriBiocon Biologics Inc1 × 142

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for Q5114. For practitioners the limit is 120 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q5114 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services1203 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital1203 Date of Service Edit: ClinicalPrescribing Information

MUE for Q5114 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5114 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5114 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5114 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q5114 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5114 carries status indicator K and is assigned to APC 9341, with a published national unadjusted payment of $29.507. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5114 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $29.51 per 10 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5114 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5114

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5114

What does HCPCS code Q5114 describe?

Q5114 is defined by CMS as "Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5114 a CPT code?

No. Q5114 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as trastuzumab-dkst (Ogivri); CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5114 reports the drug itself in 10 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5114 in October 2026?

The ASP-based payment limit is $29.507 per 10 MG, with 20% beneficiary coinsurance. The July 2026 limit was $31.945. Commercial payers use their own fee schedules.

How many units of Q5114 can be billed per day?

The practitioner Medically Unlikely Edit is 120 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to Q5114?

The October 2026 ASP crosswalk lists 4 NDCs from 2 labelers: Ogivri (Viatris - Greenstone LLC); Ogivri (Biocon Biologics Inc). For example NDC 67457-0847-44 (package size 1) equals 42 billing units of Q5114.

Does Q5114 have NCCI bundling edits?

No active practitioner PTP pairs list Q5114 as a column-1 or column-2 code in the v323r0 release.

Q5114 vs Q5113: what is the difference?

Both are HCPCS Level II codes whose descriptor names trastuzumab. What sets Q5113 apart: biosimilar trastuzumab-pkrb (Herzuma) from Cephalon, LLC. Q5114 is billed per 10 mg, limit $29.507, MUE 120; Q5113 is billed per 10 mg, limit $55.295, MUE 120. Report the code whose descriptor matches the product and setting in the record.

Q5114 vs Q5112: what is the difference?

Both are HCPCS Level II codes whose descriptor names trastuzumab. What sets Q5112 apart: biosimilar trastuzumab-dttb (Ontruzant) from Organon LLC. Q5114 is billed per 10 mg, limit $29.507, MUE 120; Q5112 is billed per 10 mg, limit $32.791, MUE 120. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.